PRTK — Paratek Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $127.83m
- $343.47m
- $160.27m
U.S. STOCKS ON THE MOVE-Occidental Petroleum, Telos, Designer Brands
Paratek Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Paratek Pharma up, Q4 revenue helped by strong Nuzyra sales
Brief: Paratek Pharmaceuticals Announces Fourth Quarter 2022 Results
Paratek Pharmaceuticals Inc expected to post earnings of 9 cents a share - Earnings Preview
Paratek Pharmaceuticals Inc expected to post earnings of 9 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Masimo, Icosavax, PayPal
U.S. STOCKS ON THE MOVE-Oatly, Yeti, OpGen
U.S. STOCKS ON THE MOVE-Gap, Levi Strauss, Novavax
Brief: Paratek Pharmaceuticals Announces Inclusion Of Nuzyra In China’S National Reimbursement Drug List
Paratek Pharmaceuticals up as key drug added to China's reimbursement list
Brief: Paratek Pharmaceuticals Receives $36.4 Mln Milestone Payment Associated With Nuzyra
Brief: Paratek Pharmaceuticals Announces Positive Data From Pilot Efficacy Study For The Treatment Of Pulmonary Anthrax
Paratek Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Paratek Pharmaceuticals Announces Commercial Availability Of U.S.-Produced Nuzyra (Omadacycline) Tablets
Paratek Pharmaceuticals jumps as drug receives 'Fast Track' designation
Brief: Paratek's Nuzyra Receives FDA Fast Track Designation For Treatment Of Pulmonary Nontuberculous Mycobacterial Disease
Paratek Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Paratek Pharmaceuticals Announces First Quarter 2022 Revenue Of $24.9 Million